Ilex Medical Ltd (TLV:ILX)
Israel · Delayed Price · Currency is ILS · Price in ILA 5,000.00
-54.00 (-1.07%)
Aug 28, 2026, 1:44 PM IDT
Ilex Medical Income Statement
Financials in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 885.35 | 930.83 | 920.37 | 916.25 | 863.28 | 1,061 | |
Revenue Growth | -4.55% | 1.14% | 0.45% | 6.13% | -18.63% | 12.10% |
Cost of Revenue | 687.77 | 718.95 | 704.06 | 689.34 | 580.37 | 681.61 |
Gross Profit | 197.57 | 211.88 | 216.31 | 226.9 | 282.91 | 379.38 |
Selling, General & Admin | 149.28 | 148.11 | 143.93 | 142.74 | 132.77 | 126.84 |
Research & Development | 7.56 | 7.97 | 7.62 | 6.85 | 5.89 | 8.35 |
Other Operating Expenses | -0.74 | - | 2 | -0.02 | -2.1 | -1.95 |
Operating Expenses | 156.1 | 156.08 | 153.54 | 149.56 | 136.56 | 133.24 |
Operating Income | 41.47 | 55.81 | 62.77 | 77.34 | 146.35 | 246.14 |
Interest Expense | -3.07 | -2.06 | -2.34 | -1.78 | -1.57 | -1.97 |
Interest & Investment Income | 3.78 | 7.53 | 7.85 | 5.74 | 1.86 | 1.86 |
Earnings From Equity Investments | -13.47 | -10.63 | -7.19 | -4.01 | -2.69 | -0.26 |
Currency Exchange Gain (Loss) | 6.07 | 9.12 | 0.22 | -5.23 | -10.27 | -1.59 |
Other Non Operating Income (Expenses) | 10.63 | 6.82 | -3.58 | -2.64 | -9.84 | 7.4 |
EBT Excluding Unusual Items | 45.41 | 66.58 | 57.73 | 69.43 | 123.85 | 251.58 |
Gain (Loss) on Sale of Investments | 7.94 | 7.43 | 4.32 | 4.37 | -2.72 | 3.78 |
Gain (Loss) on Sale of Assets | 0.13 | 0.13 | -0.46 | 0.24 | 21.96 | -0.01 |
Pretax Income | 53.47 | 74.14 | 61.6 | 74.04 | 143.09 | 255.35 |
Income Tax Expense | 14.57 | 18.58 | 15.89 | 18.51 | 34.6 | 57.87 |
Earnings From Continuing Operations | 38.9 | 55.56 | 45.7 | 55.53 | 108.49 | 197.48 |
Earnings From Discontinued Operations | - | - | -6.72 | -4.64 | -6.37 | - |
Net Income to Company | 38.9 | 55.56 | 38.98 | 50.89 | 102.12 | 197.48 |
Net Income | 38.9 | 55.56 | 38.98 | 50.89 | 102.12 | 197.48 |
Net Income to Common | 38.9 | 55.56 | 38.98 | 50.89 | 102.12 | 197.48 |
Net Income Growth | -14.70% | 42.52% | -23.39% | -50.17% | -48.29% | 63.72% |
Shares Outstanding (Basic) | 11 | 11 | 11 | 11 | 11 | 11 |
Shares Outstanding (Diluted) | 11 | 11 | 11 | 11 | 11 | 11 |
Shares Change | -0.30% | - | -0.02% | -0.79% | -0.02% | 5.73% |
EPS (Basic) | 3.49 | 4.97 | 3.48 | 4.55 | 9.05 | 17.51 |
EPS (Diluted) | 3.49 | 4.97 | 3.48 | 4.55 | 9.05 | 17.50 |
EPS Growth | -14.44% | 42.52% | -23.34% | -49.80% | -48.27% | 55.66% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 48.7 | 45.89 | 51.87 | 31.66 | 43.6 | 229.73 |
Free Cash Flow Per Share | 4.36 | 4.10 | 4.64 | 2.83 | 3.87 | 20.36 |
Dividend Per Share | 1.986 | 1.986 | 1.220 | 1.365 | 1.917 | 5.319 |
Dividend Growth | 62.87% | 62.87% | -10.63% | -28.80% | -63.97% | 0% |
Gross Margin | 22.32% | 22.76% | 23.50% | 24.76% | 32.77% | 35.76% |
Operating Margin | 4.68% | 6.00% | 6.82% | 8.44% | 16.95% | 23.20% |
Profit Margin | 4.39% | 5.97% | 4.23% | 5.55% | 11.83% | 18.61% |
Free Cash Flow Margin | 5.50% | 4.93% | 5.64% | 3.46% | 5.05% | 21.65% |
EBITDA | 74.18 | 89.16 | 96.54 | 125.06 | 196.39 | 296.63 |
EBITDA Margin | 8.38% | 9.58% | 10.49% | 13.65% | 22.75% | 27.96% |
D&A For EBITDA | 32.7 | 33.36 | 33.77 | 47.72 | 50.04 | 50.49 |
EBIT | 41.47 | 55.81 | 62.77 | 77.34 | 146.35 | 246.14 |
EBIT Margin | 4.68% | 6.00% | 6.82% | 8.44% | 16.95% | 23.20% |
Effective Tax Rate | 27.25% | 25.06% | 25.80% | 25.00% | 24.18% | 22.66% |
Advertising Expenses | - | 3.32 | 3.53 | 3.64 | 3.4 | 1.4 |